ClinicalTrials.gg

Program

romosozumab

Also written as “Romosozumab”, “Romozosumab” and “romosozumab HCP administration with PFS”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Bone Diseases, Metabolic · Osteogenesis Imperfecta · Hip Fractures, led by 2 companies.

Furthest: phase 4, since Sep 25, 202322 company-led studies, 2 open or runningNext primary completion: Jan 14, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen212 open or runningphase 4since Sep 25, 2023May 7, 2009Jan 14, 2027phase 1 · NCT07811999
UCB10 open or runningphase 3since Sep 23, 2021Sep 23, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since May 7, 2009.

  1. May 24, 2012Phase 3 study in OsteoporosisAmgen · NCT01631214 · 4,093 enrolled · United States, Argentina, Australia and more
  2. Jan 25, 2013Phase 1 study in Bone Diseases, MetabolicAmgen · NCT01825785 · 48 enrolled
  3. Feb 19, 2013Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT01796301 · 436 enrolled · United States, Argentina, Belgium and more
  4. Apr 15, 2013Phase 1 study in OsteoporosisAmgen · NCT01833754 · 24 enrolled · United States
  5. Nov 19, 2013Phase 2 study in Osteoporosis, PostmenopausalAmgen · NCT01992159 · 252 enrolled · Japan
  6. Dec 10, 2013Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT02016716 · 294 enrolled · United States, Czechia, Poland
  7. Jun 23, 2014Phase 3 study in Osteoporosis in MenAmgen · NCT02186171 · 245 enrolled · United States, Belgium, Colombia and more
  8. Jun 2, 2016Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT02791516 · 67 enrolled · Korea, Republic of
  9. Jan 30, 2018Phase 3 study in Osteoporosis, PostmenopausalAmgen · NCT03432533 · 283 enrolled · United States, Poland, United Kingdom
  10. Sep 4, 2020Phase 1 study in Osteogenesis ImperfectaAmgen · NCT04545554 · 25 enrolled · United States, Austria, Germany and more
  11. Sep 23, 2021UCB's first study: phase 3 study in OsteoporosisNew to UCBUCB · NCT05067335 · 327 enrolled · China
  12. Jul 24, 2023Phase 3 study in Osteogenesis ImperfectaAmgen · NCT05972551 · 111 enrolled · United States, Australia, Austria and more
  13. Sep 25, 2023Phase 4 study in Osteoporosis, PostmenopausalAmgen · NCT06079476 · 100 enrolled · India
  14. Sep 4, 2026Phase 1 study in Healthy ParticipantsAmgen · NCT07811999 · 308 planned · United States, United Kingdom

Ahead

  1. Jan 14, 2027Primary completion: phase 1 study in Healthy ParticipantsAmgen · NCT07811999
  2. May 4, 2027Primary completion: phase 3 study in Osteogenesis ImperfectaAmgen · NCT05972551

TargetBeta

SOST →read by rule
“Sclerostin inhibitor”ChEMBL 37, by rule

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07811999Healthy Participants · United States, United Kingdom1RecruitingAmgenJan 14, 2027308
NCT06079476Osteoporosis, Postmenopausal · India4CompletedAmgenOct 18, 2025100
NCT05972551Osteogenesis Imperfecta · United States, Australia, Austria and more3Active, not recruitingAmgenMay 4, 2027111
NCT05067335Osteoporosis · China3CompletedUCBNov 9, 2023327
NCT04545554Osteogenesis Imperfecta · United States, Austria, Germany and more1CompletedAmgenMar 30, 202325
NCT03432533Osteoporosis, Postmenopausal · United States, Poland, United Kingdom3CompletedAmgenApr 11, 2019283
NCT02791516Osteoporosis, Postmenopausal · Korea, Republic of3CompletedAmgenFeb 12, 201867
NCT02186171Osteoporosis in Men · United States, Belgium, Colombia and more3CompletedAmgenFeb 15, 2016245
NCT02016716Osteoporosis, Postmenopausal · United States, Czechia, Poland3CompletedAmgenSep 8, 2014294
NCT01992159Osteoporosis, Postmenopausal · Japan2CompletedAmgenOct 9, 2014252
NCT01833754Osteoporosis · United States1CompletedAmgenFeb 19, 201424
NCT01796301Osteoporosis, Postmenopausal · United States, Argentina, Belgium and more3CompletedAmgenMay 14, 2015436
NCT01825785Bone Diseases, Metabolic1CompletedAmgenDec 2, 200848
NCT01631214Osteoporosis · United States, Argentina, Australia and more3CompletedAmgenFeb 27, 20174,093
NCT01588509Osteoporosis · United States1CompletedAmgenNov 21, 201260
NCT01575834Osteoporosis, Postmenopausal · United States, Argentina, Australia and more3CompletedAmgenDec 14, 20157,180
NCT01101061Bone Diseases, Metabolic1CompletedAmgenNov 1, 201031
NCT01081678Hip Fractures · United States, Argentina, Australia and more2CompletedAmgenJun 30, 2012332
NCT01059435Bone Diseases, Metabolic1CompletedAmgenJul 6, 200774
NCT00950950Bone Diseases, Metabolic1CompletedAmgenAug 19, 201024
NCT00907296Fracture Healing · United States, Australia, Bulgaria and more2CompletedAmgenMar 6, 2012402
NCT00896532Bone Diseases, Metabolic2CompletedAmgenFeb 21, 2011419

How it is read

Names in the registry

  • “Romosozumab”, 19 entries
  • “Romozosumab”, 1 entry
  • “romosozumab HCP administration with PFS”, 1 entry
  • “Romosozumab 90 mg/mL”, 1 entry
  • “Romosozumab 70 mg/mL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.